breast cancer
-
An HER2 ADC Wins First-Line Breast Cancer: The Standard Just Moved
A Chinese biopharma’s HER2-targeted antibody-drug conjugate hit its primary endpoint in a first-line metastatic breast cancer trial, beating the standard THP regimen in a head-to-head…